Search Results - "Fontes, Magda S. C"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment by Fontes, Magda S. C., Dingemanse, Jasper, Halabi, Atef, Tomaszewska-Kiecana, Monika, Sidharta, Patricia N.

    Published in Scientific reports (09-11-2022)
    “…The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects by Fontes, Magda S.C., Dingemanse, Jasper, Sidharta, Patricia N.

    Published in Clinical pharmacology in drug development (01-07-2021)
    “…Aprocitentan is an orally active dual endothelin receptor antagonist currently in development for treatment of difficult‐to‐control (resistant) hypertension…”
    Get full text
    Journal Article
  5. 5

    Changes in Cx43 and NaV1.5 expression precede the occurrence of substantial fibrosis in calcineurin-induced murine cardiac hypertrophy by Fontes, Magda S C, Raaijmakers, Antonia J A, van Doorn, Tessa, Kok, Bart, Nieuwenhuis, Sylvia, van der Nagel, Roel, Vos, Marc A, de Boer, Teun P, van Rijen, Harold V M, Bierhuizen, Marti F A

    Published in PloS one (2014)
    “…In mice, the calcium-dependent phosphatase calcineurin A (CnA) induces a transcriptional pathway leading to pathological cardiac hypertrophy. Interestingly,…”
    Get full text
    Journal Article
  6. 6

    Functional consequences of abnormal Cx43 expression in the heart by Fontes, Magda S.C., van Veen, Toon A.B., de Bakker, Jacques M.T., van Rijen, Harold V.M.

    Published in Biochimica et biophysica acta (01-08-2012)
    “…The major gap junction protein expressed in the heart, connexin43 (Cx43), is highly remodeled in the diseased heart. Usually, Cx43 is down-regulated and…”
    Get full text
    Journal Article
  7. 7

    CTGF knockout does not affect cardiac hypertrophy and fibrosis formation upon chronic pressure overload by Fontes, Magda S.C, Kessler, Elise L, van Stuijvenberg, Leonie, Brans, Maike A, Falke, Lucas L, Kok, Bart, Leask, Andrew, van Rijen, Harold V.M, Vos, Marc A, Goldschmeding, Roel, van Veen, Toon A.B

    “…Abstract Background One of the main contributors to maladaptive cardiac remodeling is fibrosis. Connective tissue growth factor (CTGF), a matricellular protein…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Changes in Cx43 and Na.sub.V1.5 Expression Precede the Occurrence of Substantial Fibrosis in Calcineurin-Induced Murine Cardiac Hypertrophy by Fontes, Magda S. C, Raaijmakers, Antonia J. A, van Doorn, Tessa, Kok, Bart, Nieuwenhuis, Sylvia, van der Nagel, Roel, Vos, Marc A, de Boer, Teun P, van Rijen, Harold V. M, Bierhuizen, Marti F. A

    Published in PloS one (31-01-2014)
    “…In mice, the calcium-dependent phosphatase calcineurin A (CnA) induces a transcriptional pathway leading to pathological cardiac hypertrophy. Interestingly,…”
    Get full text
    Journal Article